The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation ProgramTomasz Sacha, Olga Grzybowska‐Izydorczyk, Joanna Niesiobędzka‐Krężel et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 7
A Multicenter Prospective Study on Efficacy and Safety of Ponatinib in Patients with Chronic Myeloid Leukemia Resistant or Intolerant to Previous Therapy: A 3-Year ReportTomasz Sacha, Olga Grzybowska‐Izydorczyk, Elżbieta Szczepanek et al.|Blood|2020Cited by 1